TABLE 4

Number of individuals with anti-Fim2 and anti-Fim3 IgG stratified by concentration in seroprevalence sera obtained in 1997 and 2007a

Data19972007
Anti-Fim2Anti-Fim3Anti-Fim2Anti-Fim3
Total no. of observations1841849595
No. (%) of observations with values of 4 to <14 EU/ml62 (34)99 (54)38 (40)39 (41)
    95% confidence interval of the %27–4146–6130–5131–52
No. (%) of observations with values of 14 to <100 EU/ml106 (58)73 (40)44 (46)45 (47)
    95% confidence interval of the %50–6533–4736–5737–58
No. (%) of observations with values of >100 EU/ml10 (5)7 (4)8 (8)8 (8)
    95% confidence interval of the %3–102–84–164–16
  • a The lower-bound value is included in each stratification. This analysis was performed with available serum samples with measurable anti-Fim2/3 IgG. In 1997, 35% of serum samples had measurable anti-Fim2/3 IgG, and 26% had measurable anti-Fim2/3 IgG in 2007. Simultaneous confidence intervals were constructed on the proportions of the samples falling into the categories chosen here, as if they arose from a multinomial distribution (rather than the underlying distribution shown in Fig. 4). This showed significant (P < 0.01) differences in the proportions arising from anti-Fim2 and anti-Fim3 IgG concentrations in 1997, complementing the Mann-Whitney test results.